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a  b  s  t  r  a  c  t
Nutritional iron deﬁciency anemia is the most common deﬁciency disorder, affecting more
than  two billion people worldwide. Oral iron supplementation is usually the ﬁrst choice
for  the treatment of iron deﬁciency anemia, but in many conditions, oral iron is less than
ideal mainly because of gastrointestinal adverse events and the long course needed to treat
the  disease and replenish body iron stores. Intravenous iron compounds consist of an iron
oxyhydroxide core, which is surrounded by a carbohydrate shell made of polymers such
as  dextran, sucrose or gluconate. The ﬁrst iron product for intravenous use was the high
molecular weight iron dextran. However, dextran-containing intravenous iron preparations
are  associated with an elevated risk of anaphylactic reactions, which made physicians reluc-
tant  to use intravenous iron for the treatment of iron deﬁciency anemia over many years.
Intravenous ferric carboxymaltose is a stable complex with the advantage of being non-
dextran-containing and a very low immunogenic potential and therefore not predisposed
to  anaphylactic reactions. Its properties permit the administration of large doses (15 mg/kg;
maximum of 1000 mg/infusion) in a single and rapid session (15-minute infusion) without
the  requirement of a test dose. The purpose of this review is to discuss some pertinent issues
in  relation to the history, pharmacology, administration, efﬁcacy, and safety proﬁle of ferric
carboxymaltose in the treatment of patients with iron deﬁciency anemia.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.IntroductionAnemia is common. Nutritional iron deﬁciency anemia (IDA)
is recognized as the most common nutritional deﬁciency
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reserved.disorder in both the developed and developing world, affecting
more  than two billion people. A 2008 World Health Organiza-te de Medula Óssea do Hospital de Clínicas de Porto Alegre, Rua
tion (WHO) report, concentrating on pre-school children and
women, estimated that worldwide one in four people were
affected by IDA, with pregnant women and preschool-age
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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Table 1 – Disadvantages of oral iron therapy.
Gastrointestinal adverse events
Lack of adherence to therapy
Insufﬁcient length of therapy
Limited duodenal absorption due to concomitant gastrointestinal











































Table 2 – Clinical indications for intravenous iron
therapy.
Post-gastrectomy/bariatric surgery
Anemia of chronic kidney disease
Intestinal malabsorption syndromes
Anemia associated to inﬂammatory diseases
Inﬂammatory bowel diseases
Anemia of cancer
Intolerance to oral iron or non-compliance to an oral regimen
Iron-refractory iron deﬁciency anemias
Hereditary hemorrhagic telangiectasias (Osler-Weber-Rendu
disease) and angiodysplasia due to other causes (in cases whenLong course therapy – 1 to 2 months to resolve anemia and 3 to 6
months to replenish body iron stores
hildren at the greatest risk.1 High prevalences of anemia are
ssociated with older age,2 and with acute and chronic condi-
ions, such as chronic kidney disease.3
In a population-based study designed to detect the preva-
ence of anemia in a healthy population of children (18 months
o 7 years) and women (14–30 years) tested in 2006–2007 in the
tate of Rio Grande do Sul, Brazil, the median prevalence of
nemia was 45.4% in 2198 children and 36.4% in 1999 women.4
he high prevalence of IDA has substantial consequences not
nly on health but also on subsequent socioeconomic issues,
ncluding decreased work capacity and productivity.1
ral  iron  therapy
ron has been used to treat anemia for more  than 300 years.
owever, it was not until the 19th century when Pierre
laud introduced ferrous sulfate that iron therapy became the
tandard treatment for IDA.4
Treatment with oral iron supplements is simple, inexpen-
ive and a relatively effective way of treating iron deﬁcient
onditions. If response does not occur within 3–4 weeks of
uitable treatment, there is no reason to continue oral iron
herapy. Rather, an explanation for failure should be sought.
n the other hand, it is very well known that oral iron is a less
han ideal treatment. Table 1 shows the main disadvantages
f this therapy.
Noncompliance with a prescribed course of oral iron is
ommon, and even in compliant patients, limited intestinal
bsorption fails to compensate for the iron needs in the pres-
nce of ongoing blood losses or inﬂammatory conditions.5–7
In addition, adequate iron stores are essential to achieve
aximum beneﬁt from erythropoiesis-stimulating agents
ESAs). Low iron stores and decreased availability of iron are
he most common reasons for resistance to the effect of these
gents. Thus, oral iron therapy should not be considered for
hronic kidney disease (CKD) patients on hemodialysis and
ancer patients receiving ESAs because of the inﬂammatory
tate. In this scenario, oral iron is poorly absorbed from the
ntestinal tract due to the upregulation of hepcidin, a pep-
ide hormone that plays a central role in iron homeostasis.8
n addition, in inﬂammatory bowel disease (IBD), the possi-
ility that iron may further damage the intestinal mucosa
hould prompt serious thought about the use of intravenous
IV) rather than oral iron therapy.9–14ntravenous  iron  therapy
reatment with IV iron in some clinical situations could
resent some advantages over oral iron, such as faster andoral iron is not tolerated or insufﬁcient for treatment)
higher increases of hemoglobin (Hb) levels and body iron
stores.15–23
For these reasons, modern formulations of IV iron
have emerged as a safe and effective alternative for IDA
management.9–14 The main clinical indications for IV iron
treatment are listed in Table 2.
Newer  intravenous  iron  formulations
In the last two years, three new IV iron compounds have been
released for clinical use in patients with IDA. Two are currently
approved for use in Europe (ferric carboxymaltose [FCM],24–29
and iron isomaltoside 1000 [Monofer®]30 and one in the United
States (Ferumoxytol [FeraHeme®]).31–33
In their pre-registration trials, all of these three new com-
pounds could potentially have a better safety proﬁle than
the more  traditional IV preparations, particularly because
these products can be given more  rapidly and in larger
doses than their predecessors. They are promising for the
complete replacement of iron within 15–60 min. The use of
FCM in Brazil was recently approved by the Brazilian Health
Regulatory Agency, Agência Nacional de Vigilância Sanitária
(ANVISA).
Ferric  carboxymaltose
FCM is a parenteral iron dextran-free product and the ﬁrst of
the new agents approved for rapid and high-dose replenish-
ment of depleted iron stores.24 FCM is an iron complex that
consists of a ferric hydroxide core stabilized by a carbohydrate
shell. The design of the macromolecular ferric hydroxide car-
bohydrate complex allows controlled delivery of iron to the
cells of the reticuloendothelial system and subsequent deliv-
ery to the iron-binding proteins, ferritin and transferrin, with
minimal risk of large amounts of ionic iron being released into
the serum.24
FCM is a stable complex with the advantage of being
non-dextran-containing and having a very low immunogenic
potential and therefore not predisposed to high risk of ana-
phylactic reactions. Its properties permit the administration
of large doses (15 mg/kg; maximum of 1000 mg/infusion) in
a single and rapid session (15-minute infusion) without the
requirement of a test dose.25–28
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Efﬁcacy  of  ferric  carboxymaltose
The therapeutic efﬁcacy of IV FCM has been evaluated in sev-
eral randomized, Phase III, open-label, controlled, multicenter
trials in a diverse range of conditions associated with absolute
or functional iron deﬁciency with or without anemia. These
conditions include patients with IBD, abnormal uterine bleed-
ing (AUB), postpartum IDA, chronic heart failure (CHF), anemia
in pregnancy in the second and third trimester, post-partum
anemia (PPA) and CKD patients on hemodialysis or not. Most
of these trials used oral iron as a comparator, and FCM was
shown to have better efﬁcacy compared to oral iron in terms
of improvement of Hb levels particularly with regard to body
iron replenishment (signiﬁcantly faster and greater with FCM
than ferrous sulfate).3,24–28,34
In most of these trials, patients received either FCM doses
of ≤1000 mg,  administered IV over ≤15 min  or oral ferrous sul-
fate (FeSulf), 325 mg  (65 mg  iron) three times daily, or 304 mg
(100 mg  iron) twice daily.3,24–28,34
FCM was usually administered until the patient’s calcu-
lated total iron replacement dose was achieved. Treatment
with FCM improved indices of anemia: Hb, ferritin and trans-
ferrin saturation [TSAT] values.34
In patients on hemodialysis (HD) with IDA secondary
to CKD, FCM demonstrated an efﬁcacy comparable to iron
sucrose (IS) in achieving an increase in Hb.34,35
In patients with IBD or PPA, improvements in Hb levels were
more rapid with FCM than with FeSulf.25,34,36
Patients with PPA receiving FCM, compared to those receiv-
ing oral iron, achieved a ≥2.0 g/dL increase in Hb earlier (seven
days versus 14 days; p-value <0.001) and were more  likely to
achieve a ≥3.0 g/dL increase in Hb at any time beginning on
Day 14 (86.3% versus 60.4%; p-value <0.001). Moreover they
were more  likely to achieve an Hb level >12.0 g/dL by the end of
the study (Day 42; 90.5% versus 68.6%, p-value <0.01). Serum
ferritin increased in the IV FCM treatment group, but not in
the oral iron group. Differences between groups were signif-
icant at each study time point. TSAT increased signiﬁcantly
at every time point in both groups; however, FCM-treated
patients showed higher TSAT at each time point after the ﬁrst
week.34,36
FCM improved the quality of life of patients to an extent
equivalent to oral FeSulf in patients with IBD or PPA,
and to a greater extent than oral FeSulf in women with
AUB.25,27,34,36
FCM also improved the quality of life as well as functional
symptoms and exercise capacity in patients with CHF.26,34
A multicenter comparative study that compared the
efﬁcacy of FCM versus IS for correcting preoperative ane-
mia  in patients undergoing major elective surgery showed
limitations of IS to achieve high-level iron repletion includ-
ing the number and frequency of doses (maximum dose
500 mg  per week) and duration of administration (60 min
for a 200 mg  dose). In contrast, FCM attained iron replen-
ishment more  frequently (82% versus 62%, respectively;
p-value = 0.007) with fewer treatment sessions [2 versus 5,
respectively; p-value = 0.001], showed a higher ﬁnal Hb level
with a trend toward a higher rate of anemia correction, and
patients received intraoperative and/or postoperative blood 2 0 1 5;3  7(6):400–405
transfusions less frequently. There were no IV iron-related life-
threatening adverse events, and the frequency of mild adverse
events was similar with both IV products.37
Ferric  carboxymaltose  safety
The safety of FCM was tested in a total of 20 phase II/III
database trials that evaluated 5799 subjects exposed to FCM, a
larger database than for any other IV iron formulation reported
to date.38
In this larger database the event rates are compared
between subjects exposed to FCM and subjects exposed to oral
iron, any IV iron, or pooled comparators (including any IV iron
formulation available at the time the trials were conducted, i.e.
IS, ferric gluconate, or low and high molecular weight iron dex-
tran, or oral iron as well as a placebo).38 When comparing FCM
to other IV iron formulations, the rates of nausea, injection site
reactions (i.e. discoloration, extravasation, or pain), headache,
hypertension, dizziness, constipation, vomiting and diarrhea
are similar. The rates of dysgeusia and hypotension are lower
in the FCM group compared with the other IV iron group.
However, the rates of decreased blood phosphate, ﬂushing,
and increased alanine aminotransferase are higher in the FCM
group than the other IV iron group. Drug-related adverse reac-
tions reported by at least 1% of treated patients are shown in
Table 3.36
Injection site reactions (i.e. discoloration, extravasation,
pain) may occur with any IV iron formulations.38 Such reac-
tions were reported in 1.6% of subjects receiving FCM in the
pooled phase II/III database compared with 1.8% of subjects
receiving any other IV iron (Table 3).38 These discolored regions
may be long lasting (several months) and can be a cosmetic
concern. It has been found that the incidence of injection site
discoloration after FCM administration may be greatly reduced
by the practice of ﬂushing the infusion catheter with saline
before withdrawing the needle to avoid dribbling of FCM into
the subcutaneous tissue.38
Hypersensitivity reactions, including some that are fatal,
are adverse events that occur to some extent for all IV iron
formulations. So far, a single case of fatality has been asso-
ciated with FCM.39 Standard warning text is required by the
FDA to be included in all the prescribing information of all
IV irons marketed in the USA, advising that patients may
present with shock, clinically signiﬁcant hypotension, loss of
consciousness, or collapse. The text states that it is necessary
to monitor patients for signs and symptoms of hypersensitiv-
ity during and after IV iron administration for at least 30 min
and until clinically stable following completion of the infu-
sion. In addition, it is stated that such agents are administered
only when personnel and therapies are immediately avail-
able for the treatment of serious hypersensitivity reactions.
Similarly, the European Medicines Agency recently completed
a review of post-marketing safety data for IV irons (includ-
ing FCM) and concluded that all IV irons have a small risk
of causing allergic reactions which can be life threatening if
40not treated promptly. In the two primary FCM 750 mg  trials,
serious anaphylactic/anaphylactoid reactions were reported
in 0.1% (2/1775) of subjects receiving FCM and 0.1% (1/1783) of
subjects receiving a comparator.38,39
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Nausea 3.1 2.8 2.5 2.2 0.112
Decreased blood phosphorus 1.9a 2a 0b 0b <0.001
Injection site reaction 1.6a 0.7b 0c 1.8a <0.001
Headache 1.4 1.1 1.1 1.3 0.453
Hypertension 1.3a 0.7b 0.1c 1.4a <0.001
Dizziness 1.2a 0.8a 0.3b 1.3a <0.001
Flushing 1.0a 0.1b,c 0b 0.2c <0.001
Increased alanine aminotransferase 1.0a 0.5b,c 0.8a,c 0.2b <0.001
Dysgeusia 0.9a 1.0a 0.2b 2.0c <0.001
Constipation 0.8a 4.1b 8.0c 0.4a <0.001
Vomiting 0.7 0.9 1.0 0.8 0.532
Diarrhea 0.5a 1.1b,c 1.6b 0.7a,c <0.001
Hypotension 0.5a 0.8a 0b 1.7c <0.001































Most of the hypertensive events in the FCM group occurred
uring the observation period immediately following study
rug administration and most of them were resolved within
0 min. The FCM prescribing information recommends mon-
toring patients for signs and symptoms of hypertension
ollowing each FCM administration.38
A transient drop in blood phosphate was a ﬁnding in the
linical trials of FCM. None of the cases of hypophosphatemia
n these trials was associated with serious adverse events.
n nearly all cases there was no clinical sign except for the
ow laboratory value.36,38,39,41,42 Hypophosphatemia is related
o an increase in ﬁbroblast growth factor 23 (FGF23) activ-
ty, an osteocyte-derived hormone that regulates phosphate
nd vitamin D homeostasis. Elevated FGF23 activity increased
rinary excretion of phosphate, decreased calcitriol levels,
nd increased parathyroid hormone levels, causing (in some
atients treated with FCM) transient, mostly asymptomatic
ypophosphatemia.38,42
Regarding tolerability and the safety proﬁle, the clinical tri-
ls with FCM evaluated 5799 subjects exposed to FCM and
ost drug-related adverse events were considered transient
nd mild to moderate in intensity. Treatment was not per-
anently discontinued in any patient due to adverse events.
hese studies concluded that FCM is well tolerated and with a
linically manageable safety proﬁle when appropriate dosing,
orrect schedule of infusion and monitoring are used.3,24–28,34
No safety concerns have been identiﬁed in breastfed
nfants of mothers receiving FCM and administration in the
econd and third trimester of pregnancy is safe and effective.43
onclusionsral iron supplements are an inexpensive and effective way of
reating IDA patients and their administration, in the absence
f inﬂammation or signiﬁcant ongoing blood loss, can correct
nemia, provided signiﬁcant doses of iron can be tolerated.In some clinical situations, oral iron is a less than ideal
treatment because of the increased rate of gastrointestinal
adverse events, particularly when using ferrous iron com-
pounds, and the long course needed to resolve anemia and
to achieve replenishment of body iron stores.
In cases where oral iron is ineffective, associated with
adverse events or cannot be used, IV iron compounds are treat-
ment options.
FCM has been available in Europe since its approval in 2007
and in the USA since 2009; it is currently marketed in over 50
countries and recently became available in Brazil.
Since 2007 several trials have been completed, conﬁrming
the safety and effectiveness of FCM in the treatment of IDA in
a variety of clinical settings.
FCM permits a much higher single dose of IV iron to be
administered over a shorter period.
Another indication for FCM is anemia associated to chronic
inﬂammation, when elevated levels of hepcidin may induce
proteolytic degradation of ferroportin molecules that are nec-
essary for transporting iron from the gastrointestinal tract to
the circulation.
The ability to treat IDA that is unresponsive to oral iron in a
broad range of patients in one or two rapid administrations is
likely to increase patients’ compliance and may improve the
quality of life and signiﬁcantly reduce healthcare costs.
FCM represents an important new therapeutic modality
that offers signiﬁcant clinical beneﬁt, and thereby can reduce
morbidity and mortality from many  pathological conditions
associated with iron deﬁciency.
Overall, FCM is considered a new optimal treatment for
parenteral iron administration, providing a very efﬁcient and
convenient means of delivering iron in patients with IDA.Conﬂicts  of  interest
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